We are a partnership across industry, academia, healthcare, government, patients and the public committed to rapidly discover, implement and commercialize ‘omics-based biomarker tests that address unmet medical needs.
Our biomarker programs harness the power of clinical, molecular and computational science to develop biomarker tests to better predict, diagnose, manage and treat a range of disease indications.
We offer flexible partnering options that provide organizations around the world with support in artificial intelligence, ‘-omics science and various biomarker workflows that will expedite diagnostic and drug development efforts.
We are committed to supporting the healthcare and research community during the COVID19 crisis through redeployment of our resources.
Click HERE to read more about how we can help.
2022 Maestre‐Batlle, D, Nygaard, UC, Huff, D, Alexis, N E, Tebbutt SJ, Turvey SE, Carlsten C, & Kocbach Bølling, A. (2022). Dibutyl phthalate exposure alters t‐cell subsets in blood from allergen‐sensitized volunteers. Indoor Air, 32(4). https://doi.org/10.1111/ina.13026 Hanson J, Liu-Fei F,Read more